Leavitt Partners November 16, 2023
The Save Rare Treatments Task Force, a new multi-sector public policy and advocacy collaboration convened by Leavitt Partners, an HMA Company, publicly launched this week and today released a letter of support for recently introduced, bipartisan, bicameral legislation. The Task Force is comprised of organizations representing persons living with rare diseases, biopharmaceutical innovators, and other health sector leaders committed to modifying the Medicare Drug Price Negotiation Program’s (MDPNP) overly narrow Orphan Drug Exclusion that undermines the discovery and development of new treatments for persons living with rare diseases.
“Approximately 30 million Americans have a rare disease,” the members wrote. “Yet, of the estimated 10,000 rare diseases, 95 percent lack a Food and Drug Administration (FDA)-approved treatment. That means most...
Today's Sponsors
Today's Sponsor